Takeda Pharmaceutical Co. (TAK)
(Real Time Quote from BATS)
$15.06 USD
+0.04 (0.27%)
Updated Sep 19, 2025 09:30 AM ET
5-Strong Sell of 5 5
B Value C Growth A Momentum A VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
TAK 15.06 +0.04(0.27%)
Will TAK be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for TAK based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for TAK
KALV Stock Moves More Than 30% in a Week: What Is Driving This Rally?
Will Strong Asceniv Sales Drive ADMA Biologics Further?
TAK: What are Zacks experts saying now?
Zacks Private Portfolio Services
Ocular Therapeutix (OCUL) Moves 8.6% Higher: Will This Strength Last?
ADMA vs Takeda: Which Plasma Therapy Stock Is the Better Buy Today?
ADMA Looks to Expand Asceniv's Label: Will This Boost Sales?
Other News for TAK
Is TAK set to breakout? NR7 shows up after sliding 0.46%
Is TAK positioned for a breakdown? 20 Day Moving Average Resistance shows up after declining 0.2%
Novavax: Endlessly Frustrating, Endlessly Fascinating - Warrants Rating Upgrade
TAK forms NR7 on September 16
Takeda Flat on Hookup with VELA